SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the election of Laura A. Brege to its board of directors. Ms. Brege will fill a vacancy on the Board and serve as a Class III director. The terms of the Class III directors expire at the annual meeting of stockholders in 2010.
